Supplementary Appendix 2: Relative ratios, seroconversion and proportion attaining the median convalescent serum level after BNT162b2 or mRNA-1273 vaccination in patients with serology at both 6-7 weeks and 12 weeks

Antibody	Weeks after second dose	Relative ratio, median (IQR)			No. (%) of patients with seroconversion			No. (%) of patients who reached convalescent level		
		BNT162b2	mRNA-1273	p-value	BNT162b2	mRNA-1273	p-value	BNT162b2	mRNA-1273	p-value
Anti-spike	6-7	1.58 (1.39-1.68)	1.73 (1.69-1.79)	< 0.001	60 (87)	61 (97)	1.00	48 (76)	60 (95)	<0.001
					n=63	n=63		n=63	n=63	
	12	1.35 (0.86-1.52)	1.97 (1.75-2.05)	<0.001	61 (97)	60 (95)		28 (44)	60 (95)	
					n=63	n=63		n=63	n=63	
Anti-RBD	6-7	1.33 (0.71-1.64)	1.44 (1.29-1.52)	0.39	58 (92)	60 (95)	0.031	33 (52)	50 (79)	<0.001
					n=63	n=63		n=63	n=63	
	12	0.75 (0.28-1.34)	1.30 (1.04-1.46)	< 0.001	53 (84)	59 (94)		20 (32)	39 (62)	
					n=63	n=63		n=63	n=63	
Anti-NP	6-7	0.055 (0.030-	0.060 (0.043-	0.24	11 (18)	6 (10)	0.38	3 (5)	6 (10)	0.69
		0.11)	0.13)		n=63	n=63		n=63	n=63	
	12	0.040 (0.020-	0.057 (0.035-	0.03	10 (16%)	4 (6%)		5 (8)	2 (3)	
		0.090)	0.11)		n=63	n=63		n=63	n=63	

Note: IQR=interquartile range, NP=nucleocapsid protein, RBD=receptor binding domain.

Note: Mann-Whitney test was used to compare antibody relative ratios at 6-7 weeks and 12 weeks while McNemar's test was used for comparison of proportions with seroconversion and reaching convalescent levels at 6-7 weeks and 12 weeks.

Appendix 2, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.